AKORN $14.59


24/5/2013 04:24 PM  |  NASDAQ : AKRX  |  Industries : Manufacturing / Pharmaceutical and Medicine Manufacturing
12 Mo. Price Change : 7% - AKRX has underperformed the S&P 500 by 18%

Get Trend Analysis Icon Get Trend Analysis

Partner Headlines

  1. Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest ...

    Benzinga

  2. Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest ROE

    Benzinga

  3. Akorn Inc. Reports Operating Results (10-Q)

    GuruFocus

  4. UPDATE: Deutsche Bank Reiterates Hold Rating, Lowers PT on Akorn

    Benzinga

  5. A Peek Into The Market Before The Trading Starts

    Benzinga

  6. Akorn Announces Approval of Generic Prometrium

    Benzinga

  7. Weekly CFO Sells Highlight: AKRX, FIO, OVRL, VRTX

    GuruFocus

  8. Benzinga's Top Initiations

    Benzinga

  9. UPDATE: Bank of America Initiates Akorn at Buy on Product, Revenue Mix

    Benzinga

  10. Weekly CFO Sells Highlight: ASGN, COF, AKRX, MCRS, GILD, ROP, PLL

    GuruFocus

  11. Akorn's Chairman Adopts 10b5-1 Trading Plan

    Benzinga

  12. Top 4 Small-Cap Stocks In The Drugs-Generic Industry With The ...

    Benzinga

  13. Piper Jaffray Reiterates Overweight Rating, $21 PT on Akorn

    Benzinga

  14. Akorn Inc. Reports Operating Results (10-Q)

    GuruFocus

  15. Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest ...

    Benzinga

  16. Health Care Sector Wrap

    FOXBusiness

  17. Quest Software, Pharmacyclics, Other Stocks Hit 52-Week Highs Monday

    FOXBusiness

  18. Earnings Scheduled For May 8

    Benzinga

  19. New drugs boost Akorn in Q2

    at IBD

  20. Akorn Earnings Beat Views, But Outlook Hits Stock

    at IBD

  21. Akorn Earnings Beat Views, But Outlook Hits Stock

    at IBD

  22. Piper Jaffray Remains Bullish on Akorn Shares

    at Benzinga

  23. Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest ...

    at Benzinga

  24. Notable Put Options Activity in Akorn

    at Benzinga

  25. Piper Jaffray Says Akorn's 2012 Guidance Leaves Room for Upside

    at Benzinga

  26. Ognar Seeks Underappreciated, Fast-Growing Companies

    at IBD

  27. End-of-Day Market Summary for December 23, 2011

    at Benzinga

  28. Hearing Akorn Recent Weakness Attributed to FDA Inspection Letter

    at Benzinga

  29. UPDATE: Deutsche Bank Maintains Buy on Akorn, Ups Target to $13

    at Benzinga

  30. UPDATE: Piper Jaffray Maintains Overweight, Raises PT to $14 on Akorn

    at Benzinga

  31. Piper Jaffray Raises PT on Akorn to $14

    at Benzinga

  32. Akorn Acquires Three Hospital-Based Branded Injectables from ...

    at Benzinga

  33. Top 4 Stocks In The Drugs-Generic Industry With The Highest Profit ...

    at Benzinga

  34. Piper Jaffray Maintains Overweight, $12 Target on Akorn

    at Benzinga

  35. Deutsche Bank Maintains Buy Rating on Akorn

    at Benzinga

  36. Weekly CFO Sells Highlight: DMAN, DISCA, TSPT, ONE, AKRX

    at GuruFocus

  37. Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest ...

    at Benzinga
People viewing AKRX also viewed: , , , , , ,
Marketplace
Trading Center